Table 1.
Patient demographics and baseline characteristics
| Variable | N = 120 |
|---|---|
| Age, years | 82.1 ± 4.0 |
| Gender, female | 67.5 (81) |
| Risk assessments | |
| STS Score, % | 4.8 ± 3.8 |
| STS score ≥ 8% | 11.7 (14) |
| EuroSCORE II | 4.7 ± 3.8 |
| NYHA Class III or IV | 99.2 (119) |
| Medical history | |
| COPD, moderate or severe | 10 (12) |
| Diabetes mellitus, medically treated | 27.5 (33) |
| History of coronary artery disease | 69.2 (83) |
| Porcelain aorta | 5.8 (7) |
| History of cerebrovascular disease | 3.3 (4) |
| Prior stroke / TIA | 10.8 (13) |
| History of atrial fibrillation | 25.0% (30) |
| Previous cardiovascular interventions | |
| Prior PTCA | 4.2 (5) |
| Prior PTCA with stenting | 26.7 (32) |
| Prior CABG | 5.8 (7) |
| Prior implanted pacemaker | 6.7 (8) |
| Conduction abnormality at baseline | |
| Any conduction abnormality | 47.5% (57) |
| AV block, 1st degree | 15.0% (18) |
| LBBB | 10.8% (13) |
| RBBB | 8.3% (10) |
| Echocardiographic measurements (core laboratory adjudicated) | |
| Aortic valve area (effective orifice area), cm2 | 0.74 ± 0.2 |
| Mean aortic valve gradient, mmHg | 40.3 ± 14.1 |
| Peak aortic valve gradient, mmHg | 65.9 ± 21.4 |
| Left ventricular ejection fraction, % | 55.8 ± 10.1 |
| Aortic regurgitation ≥ moderatea | 6.1 (7/115) |
| Mitral regurgitation ≥ moderateb | 8.3 (9/108) |
Values are mean ± standard deviation (n) or % (n)
AV atrioventricular, CABG coronary artery bypass graft, COPD chronic obstructive pulmonary disease, LBBB left bundle branch block, NYHA New York Heart Association, PTCA Percutaneous transluminal coronary angioplasty, RBBB right bundle branch block, STS Society of Thoracic Surgeons, TIA transient ischemic attack
aEvaluated as ‘moderate’ in four patients (3.5%) and ‘moderately severe’ in three patients (2.6%)
bEvaluated as ‘moderate’ in seven patients (6.5%) and ‘severe’ in two patients (1.9%)